Bausch + Lomb: Undervalued Stock Potential?

Bausch + Lomb's stock has rewarded investors with a 17.2% return in the last year. However, several valuation indicators suggest the shares are still trading below their intrinsic value. This presents a puzzle for investors, questioning why a stock with a strong value score and an estimated undervaluation is not fully reflecting its potential.

Advancements in late-stage eye therapy trials offer a promising outlook for future cash flows. These developments are factored into a discounted cash flow (DCF) model, which projects future cash generation and estimates an intrinsic value of approximately $34.26 per share. Despite this, clinical and regulatory uncertainties surrounding these therapies may temper investor confidence and limit current valuation.

The DCF analysis specifically points to a significant undervaluation, estimating Bausch + Lomb shares to be trading at a 49.9% discount. This suggests that the market is pricing in a substantial margin of safety to account for potential clinical and execution risks. Investors must weigh whether this discount adequately compensates for the inherent uncertainties in the company's development pipeline.